Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 7/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | NQO2 | P16083 | 3/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 7/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.51 |
| ▸ | TUBB | P07437 | 1/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515449 | 0.84 | CYP1A1 (0.81) | CYP1A1CYP1B1CYP1A2NQO2PTGS1 | |
| SCHEMBL9817944 | 0.84 | CYP1A1 (0.81) | CYP1A1CYP1B1CYP1A2NQO2PTGS1 | |
| SCHEMBL15460407 | 0.82 | TUBB1 (0.56) | CYP1A1CYP1B1CYP1A2NQO2PTGS1 | |
| SCHEMBL27940446 | 0.82 | CYP1A1 (0.75) | CYP1A1CYP1B1CYP1A2NQO2PTGS1 | |
| SCHEMBL4686223 | 0.81 | TUBB1 (0.56) | CYP1A1CYP1B1CYP1A2PTGS1NFE2L2 | |
| SCHEMBL4686225 | 0.81 | TUBB1 (0.56) | CYP1A1CYP1B1CYP1A2PTGS1NFE2L2 | |
| SCHEMBL3394561 | 0.80 | ALDH1A1 (0.70) | CYP1A2TTR | |
| SCHEMBL31088175 | 0.80 | BACE1 (0.56) | NFE2L2ABCG2 | |
| SCHEMBL31088177 | 0.80 | BACE1 (0.56) | NFE2L2ABCG2 | |
| SCHEMBL4679399 | 0.79 | KDM4E (0.75) | PTGS1NFE2L2PTGS2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410116-B2 | Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-04-02 | — | — | US | disclosed |
| US-20100190803-A1 | BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190803-A1 | BIS(STYRYL)PYRIMIDINE OR BIS(STYRYL)BENZENE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES FEATURING AMYLOIDS COMPRISING THE SAME AS AN ACTIVE INGREDIENT | PSEN1, APP, BACE1 | CYP1A1 104/4885CYP1B1 17/4885CYP1A2 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.